Polyphyletic_JJ Strains_NP of_IN Hepatitis_NP E_NP Virus_NP Are_NP Responsible_NP for_IN Sporadic_NP Cases_NPS of_IN Acute_NP Hepatitis_NP in_IN Japan_NP Among_IN 87_CD patients_NNS who_WP were_VBD previously_RB treated_VBN for_IN acute_JJ hepatitis_NN of_IN unknown_JJ etiology_NN between_IN 1992_CD and_CC 2001_CD at_IN five_CD hospitals_NNS in_IN Japan_NP ,_, 11_CD (_( 13_CD %_NN )_) patients_NNS were_VBD positive_JJ for_IN immunoglobulin_NN M-class_JJ antibodies_NNS to_TO hepatitis_NP E_NP virus_NN (_( HEV_NP )_) by_IN enzyme_NN immunoassay_NN and_CC had_VBD detectable_JJ HEV_NP RNA_NP by_IN reverse_JJ transcription-PCR_NN with_IN two_CD independent_JJ sets_NNS of_IN primers_NNS derived_VBN from_IN well-conserved_JJ genomic_JJ areas_NNS in_IN open_JJ reading_NN frames_NNS 1_CD and_CC 2_CD ._SENT Clinical_JJ HEV_NP infection_NN was_VBD significantly_RB associated_VBN with_IN male_JJ sex_NN (_( 9_CD of_IN 11_CD versus_CC 29_CD of_IN 76_CD patients_NNS [_SYM P_NN <_SYM 0.01_CD ]_SYM )_) and_CC older_JJR age_NN (_( 52_CD +-_NN 11_CD [_SYM mean_JJ +-_NN standard_JJ deviation_NN ]_SYM versus_FW 41_CD +-_NN 17_CD years_NNS [_SYM P_NN <_SYM 0.05_CD ]_SYM )_) ,_, and_CC its_PP$ prevalence_NN differed_VBD by_IN geographic_JJ region_NN (_( 6_CD to_TO 25_CD %_NN )_) ,_, with_IN a_DT higher_JJR rate_NN in_IN the_DT northern_JJ part_NN of_IN Japan_NP ._SENT At_IN admission_NN ,_, the_DT 11_CD patients_NNS with_IN HEV-associated_NP hepatitis_NP had_VBD elevated_VBN alanine_NN aminotransferase_NN levels_NNS of_IN 914_CD to_TO 4,850_CD IU/liter_NN ,_, and_CC all_DT but_CC 1_CD had_VBD elevated_VBN bilirubin_NN levels_NNS of_IN 1.5_CD to_TO 24.0_CD mg/dl_NN ._SENT The_DT 11_CD HEV_NP isolates_NNS were_VBD of_IN genotype_NN III_NP or_CC IV_NP and_CC were_VBD segregated_VBN into_IN three_CD groups_NNS with_IN intergroup_NN nucleotide_NN differences_NNS of_IN 9.5_CD to_TO 22.0_CD %_NN ._SENT Phylogenetic_JJ analysis_NN revealed_VBD that_IN four_CD isolates_NNS of_IN genotype_NN III_NP were_VBD closely_RB related_VBN to_TO a_DT Japanese_JJ isolate_NN ,_, while_IN the_DT other_JJ four_CD isolates_NNS of_IN the_DT same_JJ genotype_NN were_VBD nearest_IN those_DT from_IN the_DT United_NP States_NPS ._SENT The_DT remaining_VBG three_CD isolates_NNS were_VBD close_JJ to_TO known_VBN isolates_NNS of_IN genotype_NN IV_NP in_IN China_NP and_CC Taiwan_NP but_CC shared_VBD less_JJR than_IN 88_CD %_NN identity_NN with_IN them_PP ._SENT These_DT results_NNS indicate_VBP that_IN multiple_JJ genotypes_NNS of_IN HEV_NP cocirculate_NN in_IN Japan_NP and_CC contribute_VB to_TO the_DT development_NN of_IN sporadic_JJ acute_JJ hepatitis_NN ,_, with_IN the_DT prevalence_NN differing_VBG by_IN age_NN ,_, sex_NN ,_, and_CC geographic_JJ region_NN ._SENT Hepatitis_NP E_NP ,_, the_DT major_JJ form_NN of_IN acute_JJ viral_JJ hepatitis_NN in_IN adults_NNS in_IN many_JJ developing_VBG countries_NNS in_IN Asia_NP ,_, Africa_NP ,_, and_CC Latin_NP America_NP ,_, is_VBZ caused_VBN by_IN hepatitis_NP E_NP virus_NN (_( HEV_NP )_) ._SENT HEV_NP is_VBZ transmitted_VBN primarily_RB by_IN the_DT fecal-oral_JJ route_NN ,_, and_CC waterborne_JJ epidemics_NNS are_VBP characteristic_JJ of_IN hepatitis_NP E_NP and_CC may_MD occur_VB in_IN any_DT of_IN three_CD forms_NNS :_: large_JJ epidemics_NNS ,_, smaller_JJR outbreaks_NNS ,_, or_CC sporadic_JJ infections_NNS ._SENT Sporadic_JJ cases_NNS have_VBP also_RB been_VBN reported_VBN in_IN areas_NNS where_WRB HEV_NP is_VBZ not_RB considered_VBN endemic_NN ._SENT Many_JJ of_IN these_DT cases_NNS can_MD be_VB associated_VBN with_IN travel_NN to_TO regions_NNS where_WRB HEV_NP is_VBZ endemic_JJ ._SENT Recently_RB ,_, however_RB ,_, accumulating_VBG lines_NNS of_IN evidence_NN indicate_VBP that_IN HEV-associated_NP hepatitis_NP also_RB occurs_VBZ among_IN individuals_NNS in_IN developed_VBN countries_NNS with_IN no_DT history_NN of_IN travel_NN to_TO areas_NNS where_WRB HEV_NP is_VBZ endemic_JJ (_( ,_, ,_, ,_, ,_, -_: ,_, ,_, ,_, )_) ._SENT The_DT genome_NN of_IN HEV_NP is_VBZ a_DT single-stranded_JJ ,_, positive-sense_JJ RNA_NP of_IN approximately_RB 7.2_CD kb_NN and_CC contains_VBZ a_DT short_JJ 5_CD '_POS untranslated_JJ region_NN (_( UTR_NP )_) ,_, three_CD open_JJ reading_NN frames_NNS (_( ORFs_NP ;_: ORF1_NP ,_, ORF2_NP ,_, and_CC ORF3_NP )_) ,_, and_CC a_DT short_JJ 3_CD '_POS UTR_NP terminated_VBD by_IN a_DT poly(A)_JJ tract_NN ._SENT The_DT entire_JJ genomic_JJ sequence_NN of_IN HEV_NP was_VBD first_RB published_VBN in_IN 1991_CD for_IN a_DT strain_NN from_IN Myanmar_NP (_( formerly_RB called_VBN Burma_NP )_) ,_, which_WDT shared_VBD nucleotide_NN identity_NN of_IN >93_JJ %_NN across_IN the_DT genome_NN with_IN the_DT nucleotide_NN sequences_NNS of_IN additional_JJ isolates_NNS obtained_VBN from_IN China_NP ,_, India_NP ,_, Nepal_NP ,_, and_CC Pakistan_NP ._SENT In_IN addition_NN ,_, the_DT genomic_JJ sequence_NN of_IN a_DT Mexican_JJ isolate_NN that_WDT was_VBD implicated_VBN in_IN an_DT outbreak_NN that_WDT occurred_VBD in_IN Mexico_NP in_IN 1986_CD was_VBD published_VBN in_IN 1992_CD ._SENT The_DT Mexican_JJ isolate_NN (_( MEX-14_NP )_) is_VBZ distinct_JJ from_IN the_DT Burmese_JJ isolate_NN and_CC constitutes_VBZ a_DT second_JJ genotype_NN ._SENT A_DT third_JJ group_NN of_IN HEV_NP that_WDT is_VBZ distinct_JJ from_IN the_DT Burmese-like_JJ and_CC Mexican_JJ isolates_NNS has_VBZ been_VBN identified_VBN in_IN patients_NNS with_IN acute_JJ hepatitis_NN in_IN the_DT United_NP States_NPS and_CC European_JJ countries_NNS including_VBG Austria_NP ,_, Greece_NP ,_, Italy_NP ,_, Spain_NP ,_, and_CC the_DT United_NP Kingdom_NP and_CC in_IN Argentina_NP ,_, where_WRB HEV_NP is_VBZ not_RB endemic_JJ (_( ,_, ,_, -_: ,_, ,_, ,_, )_) ._SENT Extensive_JJ diversity_NN has_VBZ also_RB been_VBN noted_VBN among_IN HEV_NP isolates_VBZ from_IN patients_NNS with_IN acute_JJ hepatitis_NN in_IN China_NP and_CC Taiwan_NP ,_, which_WDT are_VBP distinct_JJ from_IN the_DT original_JJ Chinese_JJ isolates_NNS ,_, and_CC these_DT isolates_NNS constitute_VBP a_DT fourth_JJ group_NN ._SENT Accordingly_RB ,_, HEV_NP sequences_NNS have_VBP tentatively_RB been_VBN classified_VBN into_IN four_CD major_JJ genetic_JJ groups_NNS (_( genotypes_NNS I_PP to_TO IV_CD )_) ._SENT Worldwide_NP ,_, most_JJS HEV_NP infections_NNS are_VBP caused_VBN by_IN genotype_NN I_PP ,_, while_IN only_RB isolated_VBN cases_NNS of_IN infection_NN with_IN HEV_NP of_IN genotype_NN III_NP or_CC IV_NP have_VBP been_VBN described_VBN ._SENT In_IN Japan_NP ,_, clinical_JJ HEV_NP infection_NN rarely_RB occurs_VBZ ,_, and_CC most_JJS ,_, if_IN any_DT ,_, cases_NNS of_IN hepatitis_NP E_NP observed_VBD thus_RB far_RB have_VB been_VBN regarded_VBN as_IN imported_VBN cases_NNS of_IN hepatitis_NN ._SENT Recently_RB ,_, however_RB ,_, the_DT seroprevalence_NN of_IN antibodies_NNS against_IN HEV_NP (_( anti-HEV_NP )_) in_IN healthy_JJ individuals_NNS was_VBD reported_VBN to_TO range_VB from_IN 1.9_CD to_TO 14.1_CD %_NN ,_, depending_VBG on_IN the_DT geographic_JJ area_NN in_IN Japan_NP ._SENT In_IN addition_NN ,_, an_DT HEV_NP strain_NN of_IN genotype_NN III_NP (_( strain_NN JRA1_NN )_) has_VBZ been_VBN isolated_VBN from_IN a_DT Japanese_JJ patient_NN with_IN acute_JJ hepatitis_NN who_WP had_VBD never_RB been_VBN abroad_RB ,_, and_CC a_DT swine_NN HEV_NP strain_NN (_( strain_NN swJ570_NN )_) with_IN the_DT highest_JJS degree_NN of_IN similarity_NN to_TO isolate_VB JRA1_NP among_IN the_DT known_JJ HEV_NP isolates_NNS has_VBZ been_VBN isolated_VBN from_IN a_DT farm_NN pig_NN in_IN Japan_NP ,_, although_IN their_PP$ entire_JJ genomes_NNS shared_VBD only_RB 89_CD %_NN identity_NN ._SENT These_DT results_NNS indicate_VBP that_IN HEV_NP infection_NN may_MD be_VB circulating_VBG in_IN Japan_NP ._SENT Therefore_RB ,_, in_IN the_DT present_JJ study_NN ,_, we_PP tested_VBD the_DT sera_NN of_IN 87_CD patients_NNS with_IN sporadic_JJ acute_JJ hepatitis_NN of_IN unknown_JJ etiology_NN from_IN five_CD city_NN or_CC university_NN hospitals_NNS located_VBN in_IN different_JJ geographic_JJ regions_NNS in_IN Japan_NP for_IN the_DT presence_NN of_IN the_DT immunoglobulin_NN M_NN (IgM)-class_JJ anti-HEV_NP and_CC HEV_NP RNA_NP and_CC analyzed_VBD the_DT HEV_NP strains_NNS molecularly_RB to_TO define_VB the_DT region-dependent_JJ prevalence_NN of_IN clinical_JJ HEV_NP infection_NN and_CC the_DT extent_NN of_IN genetic_JJ diversity_NN among_IN the_DT HEV_NP strains_NNS that_WDT are_VBP spreading_VBG in_IN Japan_NP ._SENT Sera_NN from_IN patients_NNS with_IN sporadic_JJ cases_NNS of_IN acute_JJ hepatitis_NN and_CC blood_NN donors_NNS ._SENT |_SYM Serum_NP samples_NNS were_VBD obtained_VBN from_IN 87_CD patients_NNS (_( 38_CD males_NNS and_CC 49_CD females_NNS ;_: mean_VB +-_JJ standard_JJ deviation_NN [_SYM SD_NP ]_SYM age_NN ,_, 42.3_CD +-_NN 16.7_CD years_NNS )_) who_WP were_VBD seen_VBN at_IN five_CD city_NN or_CC university_NN hospitals_NNS located_VBN (_( from_IN north_NN to_TO south_NN )_) in_IN Sapporo_NP on_IN Hokkaido_NP Island_NP and_CC in_IN Iwate_NP ,_, Fukushima_NP ,_, Tokyo_NP ,_, and_CC Yamanashi_NP on_IN mainland_JJ Honshu_NP in_IN Japan_NP ,_, with_IN a_DT clinical_JJ diagnosis_NN of_IN sporadic_JJ acute_JJ hepatitis_NN of_IN non-ABC_NN etiology_NN ._SENT These_DT patients_NNS were_VBD seen_VBN at_IN the_DT respective_JJ hospitals_NNS during_IN the_DT past_JJ 3_CD to_TO 10_CD years_NNS (_( from_IN between_IN 1992_CD and_CC 2001_CD to_TO between_IN 1998_CD and_CC 2001_CD )_) ;_: each_DT patient_NN was_VBD from_IN the_DT same_JJ geographic_JJ region_NN where_WRB the_DT respective_JJ hospital_NN is_VBZ located_VBN ._SENT They_PP were_VBD all_RB negative_JJ for_IN anti-hepatitis_NN A_DT virus_NN (_( anti-HAV_NP )_) IgM_NP ,_, hepatitis_NP B_NP virus_NN (_( HBV_NP )_) markers_NNS (_( anti-HBV_NP core_NN IgM_NP and_CC hepatitis_NP B_NP surface_NN antigen_NN [_SYM HBsAg_NP ]_SYM )_) ,_, and_CC anti-hepatitis_NN C_NN virus_NN (_( anti-HCV_NP )_) ._SENT The_DT sera_NN were_VBD evaluated_VBN for_IN the_DT presence_NN of_IN anti-HAV_NP IgM_NP ,_, anti-HBV_NP core_NN IgM_NP ,_, HBsAg_NP ,_, and_CC anti-HCV_NP with_IN commercially_RB available_JJ kits_NNS (_( HAVAB-M_NP and_CC CORZYME-M_NP [_SYM Abbott_NP Laboratories_NPS ,_, Abbott_NP Park_NP ,_, Ill._NP ]_SYM ,_, Mycell_NP [_SYM Institute_NP of_IN Immunology_NP Co._NP Ltd._NP ,_, Tokyo_NP ,_, Japan_NP ]_SYM ,_, and_CC Abbott_NP HCV_NP PHA_NP 2nd_JJ Generation_NP [_SYM Dainabot_NP ,_, Tokyo_NP ,_, Japan_NP ]_SYM ,_, respectively_RB )_) ._SENT Periodic_JJ serum_NN samples_NNS were_VBD collected_VBN from_IN the_DT patients_NNS with_IN HEV_NP viremia_NN ._SENT In_IN addition_NN ,_, control_NN sera_NN from_IN 200_CD healthy_JJ blood_NN donors_NNS (_( 100_CD males_NNS and_CC 100_CD females_NNS ;_: age_NN range_NN ,_, 16_CD to_TO 24_CD years_NNS )_) at_IN the_DT Japanese_JJ Red_NP Cross_NP Yamaguchi_NP Blood_NP Center_NP ,_, which_WDT is_VBZ located_VBN in_IN the_DT southern_JJ part_NN of_IN Japan_NP ,_, were_VBD used_VBN for_IN determination_NN of_IN the_DT cutoff_NN values_VBZ for_IN the_DT anti-HEV_NP IgM_NP and_CC IgG_NP assays_NNS ,_, based_VBN on_IN the_DT recent_JJ report_NN of_IN Li_NP et_FW al._FW ,_, who_WP described_VBD that_IN healthy_JJ Japanese_JJ individuals_NNS of_IN less_JJR than_IN 30_CD years_NNS of_IN age_NN living_VBG in_IN the_DT southern_JJ part_NN of_IN Japan_NP were_VBD negative_JJ for_IN both_DT anti-HEV_NP IgM_NP and_CC IgG_NP ._SENT The_DT study_NN protocol_NN conformed_VBD to_TO the_DT ethical_JJ guidelines_NNS of_IN the_DT 1975_CD Declaration_NP of_IN Helsinki_NP and_CC was_VBD approved_VBN by_IN the_DT ethics_NNS committees_NNS of_IN the_DT institutions_NNS ,_, and_CC informed_JJ consent_NN was_VBD obtained_VBN from_IN each_DT patient_NN ._SENT Production_NN and_CC purification_NN of_IN recombinant_JJ HEV_NP ORF2_NP protein_NN ._SENT |_SYM A_DT recombinant_JJ HEV_NP ORF2_NP protein_NN whose_WP$ N_NP terminus_NN was_VBD truncated_VBN (_( amino_NN acid_NN residues_NNS 111_CD to_TO 660_CD of_IN ORF2_NP )_) was_VBD expressed_VBN by_IN a_DT recombinant_JJ baculovirus_NN by_IN the_DT method_NN described_VBN by_IN Li_NP et_FW al._FW ,_, with_IN the_DT following_VBG modifications_NNS ._SENT The_DT putative_JJ capsid_NN gene_NN (_( ORF2_NP )_) of_IN an_DT HEV_NP isolate_NN of_IN genotype_NN IV_NP (_( HE-J1_NP ;_: DDBJ/GenBank/EMBL_NP accession_NN no_RB ._SENT )_) was_VBD amplified_VBN by_IN reverse_JJ transcription_NN (RT)-PCR_NN with_IN the_DT following_VBG set_NN of_IN primers_NNS :_: sense_NN primer_NN ,_, 5'-GGA_NP TCCATG_NP GCT_NP GTG_NP GCC_NP CCG_NP GCC_NP CCT_NP GAT-3_NP '_'' ;_: antisense_NN primer_NN ,_, 5'-GAG_NP CTCATCAAT_NP ACT_NP CCC_NP GGG_NP TTT_NP TAC_NP C-3_NP '_POS ._SENT The_DT restriction_NN sites_NNS introduced_VBN in_IN the_DT primers_NNS (_( BamHI_NP in_IN the_DT sense_NN primer_NN and_CC SacI_NP in_IN the_DT antisense_NN primer_NN )_) are_VBP underlined_VBN ,_, and_CC the_DT truncated_JJ ORF2_NP start_NN codon_NN (_( ATG_NP )_) and_CC the_DT sequence_NN of_IN TCATCA_NP complementary_JJ to_TO two_CD in-frame_NN stop_NN codons_NNS (_( successive_JJ TGA_NP codons_NNS )_) are_VBP shown_VBN in_IN boldface_JJ ._SENT The_DT PCR_NP product_NN was_VBD cloned_VBN into_IN pT7BlueT_NN vector_NN (_( Novagen_NP ,_, Inc._NP ,_, Madison_NP ,_, Wis._NP )_) and_CC digested_VBN with_IN BamHI_NP and_CC SacI_NP ._SENT The_DT resulting_VBG 2-kb_JJ fragment_NN was_VBD inserted_VBN into_IN the_DT BglII-SacI_NP site_NN of_IN a_DT transfer_NN vector_NN ,_, pYMG_NP (_( Katakura_NP Industries_NPS Co._NP Ltd._NP ,_, Saitama_NP ,_, Japan_NP )_) ,_, and_CC sequenced_JJ ._SENT The_DT 5_CD '_POS truncated_JJ putative_JJ capsid_NN (_( ORF2_NP )_) gene_NN encoding_VBG 550_CD amino_NN acids_NNS was_VBD cloned_VBN into_IN a_DT baculovirus_NN expression_NN vector_NN and_CC expressed_VBD in_IN silkworm_NN pupae_NNS ._SENT The_DT silkworm_NN pupae_NNS were_VBD lysed_VBN in_IN 20_CD mM_JJ PIPES_NNS [_SYM piperazine-N,N'-bis(2-hydroxypropane-3-sulfonic_JJ acid_NN )_) ]_SYM buffer_NN (_( pH_NN 6.6_CD )_) containing_VBG 10_CD %_NN (_( vol/vol_NN )_) glycerol_NN ,_, 0.1_CD M_NP NaCl_NP ,_, 1_CD mM_NP phenylmethylsulfonyl_NN fluoride_NN ,_, and_CC 10_CD mM_NP benzamidine_NN and_CC were_VBD then_RB homogenated_VBN in_IN 10_CD %_NN (_( wt/vol_NN )_) Triton_NP X-100_NP ,_, followed_VBN by_IN centrifugation_NN at_IN 100,000_CD x_NN g_NN at_IN 4C_JJ for_IN 15_CD min_NN ._SENT The_DT resulting_VBG supernatant_JJ was_VBD treated_VBN with_IN polyethylene_NN glycol_NN at_IN a_DT final_JJ concentration_NN of_IN 4_CD %_NN (_( wt/vol_NN )_) ._SENT The_DT precipitates_NNS were_VBD redissolved_VBN in_IN 20_CD mM_NP Tris-HCl_NP (_( pH_NN 8.0_CD )_) and_CC purified_VBN by_IN anion-exchange_NN chromatography_NN ._SENT Following_VBG purification_NN ,_, the_DT purified_VBN protein_NN was_VBD shown_VBN to_TO produce_VB one_CD predominant_JJ band_NN of_IN 61_CD kDa_NN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN ._SENT The_DT protein_NN concentration_NN was_VBD determined_VBN with_IN a_DT protein_NN assay_NN kit_NN (_( Pierce_NP ,_, Rockford_NP ,_, Ill._NP )_) by_IN using_VBG bovine_JJ serum_NN albumin_NN as_IN a_DT standard_NN ._SENT The_DT purified_VBN recombinant_JJ capsid_NN protein_NN was_VBD used_VBN in_IN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) ._SENT ELISA_NP for_IN detecting_VBG anti-HEV_NP antibodies_NNS ._SENT |_SYM To_TO detect_VB anti-HEV_NP IgM_NP and_CC IgG_NP by_IN using_VBG purified_VBN recombinant_JJ ORF2_JJ protein_NN ,_, ELISA_NP was_VBD performed_VBN as_RB follows_VBZ ._SENT Wells_NNS of_IN microplates_NNS (_( Microlon_NP 600_CD ;_: Greiner_NP Labortechnik_NP GmbH_NP ,_, Frickenhausen_NP ,_, Germany_NP )_) were_VBD coated_VBN with_IN 50_CD mul_NN of_IN the_DT recombinant_JJ ORF2_NP protein_NN (_( 5_CD mug/ml_NN in_IN phosphate-buffered_JJ saline_NN )_) ,_, and_CC the_DT plates_NNS were_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 4_CD h._NN One_CD hundred_CD microliters_NNS of_IN saline_NN containing_VBG 40_CD %_NN (_( vol/vol_NN )_) calf_NN serum_NN (_( GIBCO-BRL_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) was_VBD added_VBN ._SENT The_DT microplates_NNS were_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 1_CD h_NN with_IN shaking_VBG ._SENT The_DT blocking_VBG buffer_NN was_VBD discarded_VBN ,_, and_CC each_DT well_NN was_VBD washed_VBN five_CD times_NNS with_IN saline_NN ._SENT To_TO test_VB for_IN anti-HEV_NP IgG_NP ,_, 50_CD mul_NN of_IN each_DT sample_NN was_VBD added_VBN to_TO each_DT well_NN at_IN a_DT dilution_NN of_IN 1:100_CD in_IN saline_NN containing_VBG 40_CD %_NN calf_NN serum_NN ._SENT The_DT microplates_NNS were_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 1_CD h_NN with_IN gentle_JJ agitation_NN and_CC were_VBD then_RB washed_VBN five_CD times_NNS with_IN washing_VBG buffer_NN (_( 0.05_CD %_NN Tween_NP 20_CD in_IN saline_NN )_) ._SENT Fifty_CD microliters_NNS of_IN phosphate-buffered_JJ saline_NN containing_VBG 25_CD %_NN (_( vol/vol_NN )_) fetal_JJ bovine_JJ serum_NN (_( Medical_NP &_CC Biological_NP Laboratories_NPS ,_, Co._NP Ltd._NP ,_, Nagoya_NP ,_, Japan_NP )_) and_CC peroxidase-conjugated_JJ mouse_NN monoclonal_NN anti-human_NP IgG_NP antibody_NN (_( G19_NP ;_: Institute_NP of_IN Immunology_NP Co._NP Ltd._NP )_) was_VBD added_VBN to_TO each_DT well_NN ._SENT The_DT microplates_NNS were_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 1_CD h_NN with_IN gentle_JJ agitation_NN and_CC then_RB washed_VBN five_CD times_NNS with_IN washing_VBG buffer_NN ._SENT Fifty_CD microliters_NNS of_IN tetramethylbenzidine_NN (_( TMB_NP )_) soluble_JJ reagent_NN (_( ScyTek_NP Laboratories_NP ,_, Logan_NP ,_, Utah_NP )_) as_IN a_DT substrate_NN was_VBD added_VBN to_TO each_DT well_NN ._SENT The_DT plate_NN was_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 10_CD min_NN in_IN the_DT dark_NN ,_, and_CC then_RB 50_CD mul_NN of_IN TMB_NP stop_NN buffer_NN (_( ScyTek_NP Laboratories_NP )_) was_VBD added_VBN to_TO each_DT well_NN ._SENT The_DT optical_JJ density_NN (_( OD_NN )_) of_IN each_DT sample_NN was_VBD read_VBN at_IN 450_CD nm_NN ._SENT For_IN the_DT anti-HEV_NP IgM_NP assay_NN ,_, peroxidase-labeled_JJ mouse_NN monoclonal_NN anti-human_NP IgM_NP antibody_NN (_( M49_NP ;_: Institute_NP of_IN Immunology_NP Co._NP Ltd._NP )_) was_VBD used_VBN in_IN place_NN of_IN the_DT enzyme-labeled_JJ anti-human_NP IgG_NP ._SENT Test_NN samples_NNS with_IN OD_JJ values_NNS equal_JJ to_TO or_CC greater_JJR than_IN the_DT cutoff_NN value_NN were_VBD considered_VBN positive_JJ for_IN anti-HEV_NP IgG_NP or_CC anti-HEV_NP IgM_NP ._SENT Detection_NN of_IN HEV_NP RNA_NP ._SENT |_SYM Total_NP RNAs_NP were_VBD extracted_VBN from_IN the_DT serum_NN sample_NN with_IN guanidinium_NN thiocyanate_NN and_CC phenol-chloroform_NN with_IN the_DT TRIZOL_NP LS_NP reagent_NN (_( Invitrogen_NP ,_, Groningen_NP ,_, The_DT Netherlands_NPS )_) ._SENT The_DT RNA_NP preparation_NN thus_RB obtained_VBN was_VBD reverse_RB transcribed_VBN with_IN SuperScript_NP II_NP RNase_NP H-_NP reverse_JJ transcriptase_NN (_( GIBCO-BRL_NP )_) and_CC an_DT antisense_NN primer_NN (_( primer_NN HE040_NP ;_: 5'-CCC_NP TTR_NP TCC_NP TGC_NP TGA_NP GCR_NP TTC_NP TC-3_NP '_'' [_SYM R_NP =_SYM A_NP or_CC G_NP ]_SYM )_) specific_JJ for_IN the_DT HEV_NP ORF2_NP sequence_NN and_CC was_VBD then_RB subjected_VBN to_TO nested_VBN PCR_NP in_IN the_DT presence_NN of_IN TaKaRa_NP Ex_NP Taq_NP (_( TaKaRa_NP Shuzo_NP ,_, Shiga_NP ,_, Japan_NP )_) ._SENT A_DT part_NN of_IN the_DT ORF2_NP sequence_NN was_VBD amplified_VBN with_IN the_DT primer_NN pair_NN HE044_NP (_( sense_NN primer_NN ;_: 5'-CAA_NP GGH_NP TGG_NP CGY_NP TCK_NP GTT_NP GAG_NP AC-3_NP '_'' [_SYM H_NP =_SYM A_NP ,_, T_NN ,_, or_CC C_NP ;_: Y_NP =_SYM T_NN or_CC C_NP ;_: and_CC K_NP =_SYM G_NN or_CC T_NN ]_SYM )_) and_CC HE040_NP in_IN the_DT first_JJ round_NN and_CC HE110-2_NP (_( sense_NN primer_NN ;_: mixture_NN of_IN three_CD sequences_NNS ,_, 5'-GYT_NP CKG_NP TTG_NP AGA_NP CCT_NP CYG_NP GGG_NP T-3_NP '_POS ,_, 5'-GYT_NP CKG_NP TTG_NP AGA_NP CCA_NP CGG_NP GYG_NP T-3_NP '_POS ,_, and_CC 5'-GYT_NP CKG_NP TTG_NP AGA_NP CCT_NP CTG_NP GTG_NP T-3_NP '_'' [_SYM common_JJ nucleotides_NNS are_VBP underlined_VBN ]_SYM )_) and_CC HE041_NP (_( antisense_NN primer_NN ;_: 5'-TTM_NP ACW_NP GTC_NP RGC_NP TCG_NP CCA_NP TTG_NP GC-3_NP '_'' [_SYM M_NP =_SYM A_NP or_CC C_NP ,_, W_NP =_SYM A_DT or_JJ T_NN ]_SYM )_) in_IN the_DT second_JJ round_NN (_( ORF2_NP PCR_NP )_) ._SENT The_DT PCR_NP amplification_NN was_VBD carried_VBN out_RP for_IN 35_CD cycles_NNS in_IN the_DT first_JJ round_NN (_( 94C_NN for_IN 30_CD s_NNS [_SYM an_DT additional_JJ 2_CD min_NN was_VBD used_VBN in_IN the_DT first_JJ cycle_NN ]_SYM ,_, 55C_NN for_IN 30_CD s_NNS ,_, 72C_JJ for_IN 75_CD s_NNS [_SYM an_DT additional_JJ 7_CD min_NN was_VBD used_VBN in_IN the_DT last_JJ cycle_NN ]_SYM )_) and_CC for_IN 25_CD cycles_NNS in_IN the_DT second_JJ round_NN under_IN the_DT same_JJ conditions_NNS used_VBN for_IN the_DT first_JJ round_NN except_IN that_DT extension_NN was_VBD carried_VBN out_RP for_IN 60_CD s._NNS The_DT size_NN of_IN the_DT amplification_NN product_NN of_IN the_DT first-round_NP PCR_NP was_VBD 506_CD bp_NN ,_, and_CC that_IN of_IN the_DT amplification_NN product_NN of_IN the_DT second-round_JJ PCR_NP was_VBD 458_CD bp_NN ._SENT The_DT amplification_NN products_NNS were_VBD electrophoresed_VBN on_IN a_DT 1.5_CD %_NN (_( wt/vol_NN )_) NuSieve_NP 3:1_CD agarose_NN gel_NN (_( FMC_NP BioProducts_NP ,_, Rockland_NP ,_, Maine_NP )_) ,_, stained_VBN with_IN ethidium_NN bromide_NN ,_, and_CC photographed_VBN under_IN UV_NP light_NN ._SENT The_DT RT-PCR_NP assay_NN was_VBD performed_VBN in_IN duplicate_NN ,_, and_CC reproducibility_NN was_VBD confirmed_VBN ._SENT To_TO confirm_VB the_DT presence_NN of_IN HEV_NP RNA_NP ,_, a_DT part_NN of_IN ORF1_NP was_VBD amplified_VBN by_IN nested_VBN RT-PCR_NP with_IN the_DT primer_NN sets_VBZ HE090_NP (_( sense_NN primer_NN ;_: 5'-GCA_NP GAC_NP CAC_NP RTA_NP TGT_NP GGT_NP CGA_NP YGC_NP C-3_NP '_'' )_) and_CC HE094_NP (_( antisense_NN primer_NN ;_: 5'-TGG_NP CGG_NP RMC_NP ATN_NP GCC_NP TCB_NP GCR_NP ACA_NP TC-3_NP '_'' [_SYM N_NP =_SYM A_NP ,_, G_NP ,_, T_NN ,_, or_CC C_NP ;_: B_NP =_SYM G_NP ,_, T_NN ,_, or_CC C_NP ]_SYM )_) in_IN the_DT first_JJ round_NN and_CC HE092_NP (_( sense_NN primer_NN ;_: 5'-TGT_NP GGT_NP CGA_NP YGC_NP CAT_NP GGA_NP GGC_NP CCA-3_NP '_'' )_) and_CC HE095_NP (_( antisense_NN primer_NN ;_: 5'-CCR_NP TCR_NP AAR_NP CAG_NP TAA_NP GTS_NP CGG_NP TC-3_NP '_'' [_SYM S_NP =_SYM G_NP or_CC C_NP ]_SYM )_) in_IN the_DT second_JJ round_NN under_IN the_DT same_JJ conditions_NNS as_IN those_DT described_VBN above_IN for_IN the_DT ORF2_NP PCR_NP ;_: they_PP generated_VBD amplification_NN products_NNS of_IN 567_CD and_CC 459_CD bp_NN ,_, respectively_RB ._SENT To_TO avoid_VB contamination_NN during_IN PCR_NP procedures_NNS ,_, the_DT guidelines_NNS of_IN Kwok_NP and_CC Higuchi_NP were_VBD strictly_RB observed_VBN ._SENT Two_CD negative_JJ controls_NNS and_CC one_CD positive_JJ control_NN were_VBD included_VBN for_IN every_DT 17_CD test_NN samples_NNS ._SENT Results_NNS were_VBD recorded_VBN only_RB when_WRB false-positive_JJ results_NNS were_VBD not_RB obtained_VBN for_IN the_DT negative_JJ controls_NNS and_CC HEV_NP RNA_NP was_VBD detected_VBN in_IN the_DT positive_JJ control_NN ._SENT The_DT negative_JJ control_NN was_VBD water_NN treated_VBN the_DT same_JJ way_NN as_IN the_DT serum_NN samples_NNS ._SENT The_DT positive_JJ control_NN was_VBD serum_NN from_IN a_DT Nepali_JJ patient_NN with_IN a_DT sporadic_JJ case_NN of_IN acute_JJ hepatitis_NN E_NN caused_VBN by_IN HEV_NP of_IN genotype_NN I_PP ,_, used_VBN at_IN a_DT dilution_NN of_IN 1:1,000_CD in_IN anti-HEV-negative_JJ human_JJ sera_NN obtained_VBN from_IN healthy_JJ individuals_NNS ._SENT The_DT nested_VBN RT-PCRs_NN used_VBN in_IN the_DT present_JJ study_NN had_VBD sensitivities_NNS comparable_JJ to_TO that_DT of_IN a_DT reported_VBN method_NN for_IN the_DT detection_NN of_IN HEV_NP RNA_NP in_IN the_DT serum_NN from_IN the_DT Nepali_JJ patient_NN and_CC representative_JJ serum_NN samples_NNS from_IN patients_NNS with_IN hepatitis_NP E_NP in_IN the_DT present_JJ study_NN ._SENT The_DT sequences_NNS of_IN the_DT primers_NNS mentioned_VBD above_IN were_VBD chosen_VBN from_IN well-conserved_JJ regions_NNS of_IN the_DT entire_JJ HEV_NP genome_NN by_IN comparing_VBG 19_CD known_VBN human_JJ and_CC 2_CD known_JJ swine_NN HEV_NP sequences_NNS to_TO develop_VB two_CD universal_JJ RT-PCR_NP assays_NNS that_WDT are_VBP capable_JJ of_IN detecting_VBG HEV_NP strains_NNS with_IN significant_JJ sequence_NN variations_NNS ._SENT The_DT HEV_NP sequences_NNS were_VBD as_RB follows_VBZ :_: B1_JJ and_CC B2_JJ in_IN Burma_NP ;_: C1_NP ,_, C2_NP ,_, C3_NP ,_, C4_NP ,_, C5_NP ,_, and_CC C6_NP in_IN China_NP ;_: I1_NP ,_, I2_NP ,_, and_CC I3_NP in_IN India_NP ;_: Ne1_NP in_IN Nepal_NP ;_: and_CC P1_NP and_CC P2_NP in_IN Pakistan_NP in_IN genotype_NN I_PP (_( the_DT abbreviations_NNS used_VBN for_IN the_DT HEV_NP isolates_NNS are_VBP in_IN accordance_NN with_IN the_DT recent_JJ report_NN by_IN Schlauder_NP and_CC Mushahwar_NP )_) ;_: MEX-14_NP in_IN Mexico_NP in_IN genotype_NN II_NP ;_: US1_NP and_CC US2_NP in_IN the_DT United_NP States_NPS and_CC JRA1_NP in_IN Japan_NP in_IN genotype_NN III_NP ;_: and_CC T1_NP in_IN China_NP in_IN genotype_NN IV_NP as_RB well_RB as_IN swine_NN HEV_NP isolates_VBZ in_IN genotype_NN III_NP (_( swUS1_JJ in_IN the_DT United_NP States_NPS and_CC swJ570_NN in_IN Japan_NP )_) (_( see_VB Table_NN for_IN the_DT DDBJ/GenBank/EMBL_NP databases_NNS accession_VBP numbers_NNS for_IN each_DT isolate_NN )_) ._SENT Sequence_NN analysis_NN of_IN PCR_NP products_NNS ._SENT |_SYM The_DT amplification_NN products_NNS were_VBD sequenced_VBN on_IN both_DT strands_NNS either_CC directly_RB or_CC after_IN cloning_VBG into_IN the_DT pT7BlueT_NN vector_NN by_IN using_VBG the_DT BigDye_NP Terminator_NP Cycle_NP Sequencing_NP Ready_JJ Reaction_NN kit_NN (_( Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT Sequence_NN analysis_NN was_VBD performed_VBN with_IN Genetyx-Mac_NP software_NN (_( version_NN 10.1.6_CD ;_: Software_NP Development_NP ,_, Tokyo_NP ,_, Japan_NP )_) and_CC ODEN_NP software_NN (_( version_NN 1.1.1_CD )_) from_IN the_DT DNA_NP Data_NP Bank_NP of_IN Japan_NP (_( DDBJ_NP ;_: National_NP Institute_NP of_IN Genetics_NP ,_, Mishima_NP ,_, Japan_NP )_) ._SENT Sequence_NN alignments_NNS were_VBD generated_VBN with_IN the_DT CLUSTAL_NP W_NP program_NN (_( version_NN 1.8_CD )_) ._SENT Phylogenetic_JJ trees_NNS were_VBD constructed_VBN by_IN the_DT neighbor-joining_NN method_NN ,_, based_VBN on_IN the_DT partial_JJ nucleotide_NN sequence_NN of_IN the_DT ORF1_JJ region_NN (_( 287_CD nucleotides_NNS [_SYM nt_NNS ]_SYM )_) or_CC the_DT ORF2_NP region_NN (_( 301_CD nt_NNS )_) ._SENT Bootstrap_NN values_NNS were_VBD determined_VBN on_IN 1,000_CD resamplings_NNS of_IN the_DT data_NN sets_VBZ ._SENT The_DT final_JJ tree_NN was_VBD obtained_VBN with_IN the_DT TreeView_NP program_NN (_( version_NN 1.6.6_CD )_) ._SENT Nucleotide_NN sequence_NN accession_NN numbers_NNS ._SENT |_SYM The_DT sequences_NNS determined_VBN in_IN the_DT present_JJ study_NN have_VBP been_VBN deposited_VBN in_IN the_DT DDBJ/GenBank/EMBL_NP nucleotide_NN databases_NNS under_IN accession_NN nos._JJ to_TO ._SENT TABLE_NN 1_CD |_SYM Characteristics_NN of_IN the_DT 87_CD patients_NNS with_IN acute_JJ hepatitis_NN of_IN unknown_JJ etiology_NN enrolled_VBN in_IN the_DT present_JJ study_NN TABLE_NP 4_CD |_SYM Comparison_NN of_IN partial_JJ nucleotide_NN sequences_NNS of_IN 11_CD HEV_NP isolates_NNS in_IN groups_NNS A_DT to_TO C_NP obtained_VBN in_IN the_DT present_JJ study_NN among_IN each_DT other_JJ and_CC with_IN those_DT of_IN 21_CD human_NN and_CC swine_NN HEV_NP isolates_NNS whose_WP$ entire_JJ or_CC nearly_RB entire_JJ genomic_JJ sequence_NN is_VBZ known_VBN Prevalence_NN of_IN IgM-class_NP and_CC IgG-class_NP anti-HEV_NP ._SENT |_SYM To_TO determine_VB the_DT cutoff_NN value_NN in_IN the_DT anti-HEV_NP IgM_NP assay_NN ,_, 200_CD control_NN serum_NN samples_NNS were_VBD used_VBN as_IN a_DT panel_NN ._SENT The_DT OD_JJ values_NNS ranged_VBN from_IN 0.010_CD to_TO 0.352_CD ,_, and_CC the_DT value_NN of_IN 0.353_CD ,_, which_WDT was_VBD calculated_VBN to_TO be_VB six_CD SDs_NNS above_IN the_DT mean_JJ value_NN (_( 0.068_CD )_) ,_, was_VBD used_VBN as_IN the_DT tentative_JJ cutoff_NN value_NN ._SENT Similarly_RB ,_, in_IN the_DT assay_NN of_IN anti-HEV_NP IgG_NP ,_, OD_NN values_NNS ranging_VBG from_IN 0.002_CD to_TO 0.150_CD were_VBD obtained_VBN for_IN the_DT 200_CD control_NN serum_NN samples_NNS ;_: the_DT OD_JJ value_NN of_IN 0.152_CD (_( mean_NN +_SYM 6_CD SDs_NNS )_) was_VBD used_VBN as_IN the_DT cutoff_NN value_NN for_IN anti-HEV_NP IgG_NP ._SENT By_IN using_VBG these_DT cutoff_NN values_NNS ,_, serum_NN samples_NNS obtained_VBN from_IN the_DT 87_CD patients_NNS at_IN admission_NN were_VBD tested_VBN for_IN anti-HEV_NP ._SENT The_DT sera_NN from_IN 11_CD patients_NNS were_VBD positive_JJ for_IN anti-HEV_NP IgM_NP ,_, with_IN the_DT OD_JJ values_NNS ranging_VBG from_IN 1.638_CD to_TO >3.0_NN ;_: those_DT for_IN the_DT remaining_VBG 76_CD patients_NNS ranged_VBN from_IN 0.022_CD to_TO 0.283_CD ._SENT Anti-HEV_NP IgG_NP was_VBD detectable_JJ in_IN 16_CD patients_NNS including_VBG the_DT 11_CD patients_NNS with_IN anti-HEV_NP IgM_NP ._SENT The_DT OD_JJ values_NNS for_IN anti-HEV_NP IgG_NP in_IN 11_CD patients_NNS with_IN anti-HEV_NP IgM_NP exceeded_VBD 2.6_CD ,_, those_DT for_IN the_DT 5_CD patients_NNS without_IN anti-HEV_NP IgM_NP ranged_VBD from_IN 0.175_CD to_TO 0.660_CD ,_, and_CC those_DT for_IN the_DT remaining_VBG 71_CD patients_NNS ranged_VBN from_IN 0.014_CD to_TO 0.146_CD ._SENT The_DT assays_NNS were_VBD done_VBN at_IN least_JJS in_IN triplicate_NN ,_, and_CC reproducibility_NN was_VBD confirmed_VBN ._SENT Prevalence_NN of_IN HEV_NP RNA_NP ._SENT |_SYM The_DT serum_NN samples_NNS obtained_VBN from_IN all_DT 87_CD patients_NNS at_IN admission_NN were_VBD tested_VBN for_IN HEV_NP RNA_NP by_IN RT-PCR_NP with_IN ORF2-specific_JJ primers_NNS ._SENT HEV_NP RNA_NP was_VBD detected_VBN in_IN the_DT serum_NN of_IN all_DT 11_CD patients_NNS with_IN anti-HEV_NP IgM_NP ,_, and_CC it_PP was_VBD not_RB detected_VBN in_IN the_DT remaining_VBG 76_CD patients_NNS who_WP were_VBD negative_JJ for_IN anti-HEV_NP IgM_NP ._SENT A_DT second_JJ RT-PCR_NP assay_NN with_IN ORF1-specific_JJ primers_NNS confirmed_VBD these_DT positive_JJ and_CC negative_JJ results_NNS ._SENT Of_IN interest_NN ,_, the_DT prevalence_NN of_IN HEV_NP RNA_NP differed_VBD by_IN geographic_JJ region_NN ,_, ranging_VBG from_IN 6_CD %_NN (_( 2_CD of_IN 35_CD patients_NNS )_) in_IN the_DT central_JJ part_NN of_IN the_DT Japanese_JJ mainland_NN (_( Tokyo_NP and_CC Yamanashi_NP )_) to_TO 25_CD %_NN (_( 4_CD of_IN 16_CD patients_NNS )_) in_IN Sapporo_NP on_IN Hokkaido_NP ,_, the_DT northernmost_JJ island_NN of_IN Japan_NP ,_, with_IN the_DT difference_NN being_VBG statistically_RB significant_JJ (_( P_NN <_0.05). 1,000_CD IU/liter_NN ._SENT Despite_IN the_DT marked_JJ elevation_NN of_IN ALT_NP and_CC AST_NP levels_NNS at_IN the_DT initial_JJ examination_NN ,_, the_DT abnormal_JJ liver_NN function_NN test_NN values_NNS normalized_VBD rapidly_RB within_IN 1_CD month_NN in_IN nine_CD patients_NNS but_CC persisted_VBD until_IN 35_CD or_CC 53_CD days_NNS after_IN admission_NN in_IN the_DT remaining_VBG two_CD patients_NNS ;_: one_CD of_IN these_DT patients_NNS (_( patient_NN 3_CD )_) had_VBD severe_JJ jaundice_NN ,_, and_CC the_DT condition_NN of_IN the_DT other_JJ patient_NN (_( patient_NN 11_CD )_) was_VBD complicated_VBN by_IN duodenal_JJ ulcer_NN during_IN the_DT hospital_NN admission_NN ._SENT Ten_CD patients_NNS developed_VBD jaundice_NN and_CC had_VBD bilirubinemia_NN with_IN an_DT increased_VBN bilirubin_NN level_NN of_IN 1.5_CD to_TO 24.0_CD mg/dl_NN ,_, indicating_VBG that_IN most_JJS patients_NNS contracted_VBD moderate_JJ to_TO severe_JJ cholestasis_NN ._SENT Of_IN note_NN ,_, the_DT bilirubinemia_NN continued_VBD in_IN four_CD patients_NNS (_( patients_NNS 3_CD ,_, 4_CD ,_, 7_CD ,_, and_CC 11_CD )_) even_RB after_IN normalization_NN of_IN the_DT ALT_NP and_CC AST_NP levels_NNS ._SENT When_WRB the_DT 11_CD patients_NNS with_IN HEV_NP viremia_NNS were_VBD compared_VBN with_IN the_DT remaining_VBG 76_CD patients_NNS who_WP were_VBD negative_JJ for_IN HEV_NP RNA_NP ,_, the_DT 11_CD patients_NNS with_IN HEV_NP viremia_NNS were_VBD significantly_RB older_JJR (_( P_NN <_SYM 0.05_CD )_) ,_, consisted_VBN of_IN a_DT higher_JJR percentage_NN of_IN male_JJ patients_NNS (_( P_NN <_SYM 0.01_CD )_) ,_, and_CC had_VBD higher_JJR peak_NN total_JJ bilirubin_NN and_CC peak_JJ ALT_JJ levels_NNS (_( P_NN <_SYM 0.05_CD ,_, P_NN <_0.01, 4_CD mg/dl_NN )_) (_( P_NN <_0.01), 1,000_CD IU/liter_NP )_) (_( P_NN <_0.005), 800_CD IU/liter_NP )_) (_( P_NN <_SYM 0.05_CD )_) ._SENT Detection_NN of_IN anti-HEV_NP and_CC HEV_NP RNA_NP in_IN follow-up_NN sera_NN from_IN infected_JJ patients_NNS ._SENT |_SYM Figure_NN illustrates_VBZ the_DT anti-HEV_NP IgM_NP and_CC HEV_NP RNA_NP profiles_NNS associated_VBN with_IN HEV_NP infection_NN in_IN five_CD patients_NNS ._SENT Five_CD to_TO seven_CD additional_JJ serum_NN samples_NNS were_VBD available_JJ from_IN these_DT five_CD patients_NNS (_( patients_NNS 2_CD to_TO 5_CD and_CC 10_CD )_) during_IN the_DT follow-up_NN period_NN of_IN 115_CD to_TO 287_CD days_NNS after_IN admission_NN ._SENT HEV_NP RNA_NP remained_VBD detectable_JJ in_IN serum_NN until_IN 12_CD to_TO 35_CD days_NNS after_IN admission_NN and_CC even_RB on_IN day_NN 23_CD ,_, when_WRB the_DT liver_NN function_NN test_NN values_NNS had_VBD returned_VBN to_TO nearly_RB normal_JJ levels_NNS in_IN patient_JJ 10_CD ._SENT The_DT anti-HEV_NP IgM_NP antibody_NN levels_NNS were_VBD the_DT highest_JJS at_IN admission_NN and_CC then_RB decreased_VBD rapidly_RB in_IN all_DT patients_NNS except_IN one_CD (_( patient_NN 3_CD )_) ,_, who_WP continued_VBD to_TO have_VB an_DT IgM_NP antibody_NN level_NN of_IN greater_JJR than_IN 3.0_CD until_IN 69_CD days_NNS after_IN admission_NN ._SENT A_DT low_JJ level_NN of_IN IgM_NP antibody_NN was_VBD detectable_JJ up_RB through_IN the_DT end_NN of_IN the_DT observation_NN period_NN in_IN three_CD patients_NNS (_( 147_CD days_NNS in_IN patient_JJ 3_CD ,_, 259_CD days_NNS in_IN patient_JJ 4_CD ,_, and_CC 287_CD days_NNS in_IN patient_NN 10_CD )_) ,_, but_CC disappeared_VBD at_IN 80_CD days_NNS in_IN patient_JJ 2_CD and_CC 141_CD days_NNS in_IN patient_JJ 5_CD ._SENT The_DT IgG_NP antibody_NN level_NN was_VBD as_RB high_JJ as_IN 3.0_CD OD_JJ units_NNS at_IN admission_NN in_IN all_DT patients_NNS and_CC persisted_VBD at_IN high_JJ levels_NNS ._SENT There_EX was_VBD no_DT discernible_JJ reduction_NN in_IN the_DT IgG_NP antibody_NN level_NN through_IN the_DT end_NN of_IN the_DT observation_NN period_NN ._SENT Genetic_JJ heterogeneity_NN of_IN HEV_NP isolates_NNS recovered_VBD from_IN Japanese_JJ patients_NNS with_IN hepatitis_NP E._NP |_SYM The_DT amplification_NN products_NNS of_IN ORF1_NP and_CC ORF2_NP (_( both_CC 412_CD nt_NNS ;_: primer_JJR sequences_NNS at_IN both_DT ends_NNS excluded_VBD )_) from_IN 11_CD viremic_JJ patients_NNS were_VBD sequenced_VBN and_CC compared_VBN ._SENT The_DT 11_CD HEV_NP isolates_NNS ,_, designated_VBN HE-JA1_NP to_TO HE-JA11_NP ,_, were_VBD segregated_VBN into_IN three_CD groups_NNS (_( groups_NNS A_DT to_TO C_NP ;_: tentatively_RB named_VBN only_RB in_IN this_DT paper_NN )_) on_IN the_DT basis_NN of_IN the_DT nucleotide_NN sequence_NN ._SENT Group_NP A_NP comprised_VBD HE-JA5_NP ,_, HE-JA6_NP ,_, HE-JA9_NP ,_, and_CC HE-JA11_NP ;_: group_NN B_NN comprised_VBN HE-JA4_NP ,_, HE-JA7_NP ,_, HE-JA8_NP ,_, and_CC HE-JA10_NP ;_: and_CC group_NN C_NN comprised_VBN HE-JA1_NP ,_, HE-JA2_NP ,_, and_CC HE-JA3_NP ._SENT The_DT intragroup_NN nucleotide_NN sequence_NN identities_NNS were_VBD 88.8_CD to_TO 98.8_CD %_NN for_IN the_DT ORF1_JJ sequence_NN and_CC 88.3_CD to_TO 98.5_CD %_NN for_IN the_DT ORF2_NP sequence_NN ,_, while_IN the_DT intergroup_NN nucleotide_NN sequence_NN identities_NNS were_VBD only_RB 79.3_CD to_TO 90.5_CD %_NN for_IN the_DT ORF1_JJ sequence_NN and_CC 78.0_CD to_TO 89.1_CD %_NN for_IN the_DT ORF2_NP sequence_NN ._SENT When_WRB the_DT sequences_NNS of_IN the_DT group_NN A_DT isolates_NNS were_VBD compared_VBN with_IN those_DT of_IN HEV_NP isolates_NNS whose_WP$ entire_JJ or_CC nearly_RB entire_JJ sequence_NN is_VBZ known_VBN ,_, the_DT group_NN A_DT isolates_NNS were_VBD found_VBN to_TO be_VB closely_RB related_VBN to_TO human_JJ HEV_NP (_( JRA1_NP )_) and_CC swine_NN HEV_NP (_( swJ570_NN )_) of_IN Japanese_JJ origin_NN ,_, and_CC the_DT group_NN B_NN isolates_NNS were_VBD most_RBS homologous_JJ to_TO human_JJ HEV_NP (_( US1_NP and_CC US2_NP )_) and_CC swine_NN HEV_NP (_( swUS1_JJ )_) of_IN U.S._NP origin_NN ;_: both_DT group_NN A_DT and_CC group_NN B_NN isolates_NNS were_VBD classifiable_JJ into_IN genotype_NN III_NP ._SENT The_DT group_NN C_NN isolates_NNS were_VBD closest_JJS to_TO the_DT T1_JJ isolate_NN of_IN genotype_NN IV_NP ,_, which_WDT was_VBD recovered_VBN from_IN a_DT patient_NN in_IN China_NP with_IN a_DT sporadic_JJ case_NN of_IN acute_JJ hepatitis_NN ,_, but_CC they_PP had_VBD ORF1_JJ and_CC ORF2_JJ nucleotide_NN sequence_NN similarities_NNS of_IN <90%_compared 70_CD %_NN are_VBP indicated_VBN for_IN the_DT major_JJ nodes_NNS as_IN a_DT percentage_NN of_IN the_DT data_NNS obtained_VBN from_IN 1,000_CD resamplings_NNS ._SENT For_IN visual_JJ clarity_NN ,_, HEV_NP isolates_VBZ of_IN Japanese_JJ origin_NN ,_, including_VBG those_DT described_VBN in_IN previous_JJ reports_NNS (_( JRA1_NP and_CC swJ570_NP )_) ,_, are_VBP indicated_VBN by_IN shaded_JJ circles_NNS with_IN the_DT tentative_JJ designation_NN of_IN groups_NNS A_DT to_TO C_NP (_( see_VB Table_NP )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Phylogenetic_JJ tree_NN constructed_VBN by_IN the_DT neighbor-joining_NN method_NN based_VBN on_IN the_DT partial_JJ nucleotide_NN sequence_NN (_( 301_CD nt_NNS )_) of_IN the_DT ORF2_JJ region_NN of_IN 73_CD human_NN and_CC swine_NN isolates_NNS ._SENT Phylogenetic_JJ tree_NN constructed_VBN by_IN the_DT neighbor-joining_NN method_NN based_VBN on_IN the_DT partial_JJ nucleotide_NN sequence_NN (_( 301_CD nt_NNS )_) of_IN the_DT ORF2_JJ region_NN of_IN 73_CD human_NN and_CC swine_NN isolates_NNS ._SENT In_IN addition_NN to_TO 21_CD reported_VBD human_JJ and_CC swine_NN HEV_NP isolates_VBZ of_IN genotypes_NNS I_PP to_TO IV_NP whose_WP$ entire_JJ or_CC nearly_RB entire_JJ sequence_NN is_VBZ known_VBN ,_, 40_CD reported_VBD isolates_NNS of_IN genotype_NN III_NP or_CC IV_NP whose_WP$ partial_JJ sequence_NN of_IN 301_CD ,_, 304_CD ,_, 346_CD ,_, 348_CD ,_, 421_CD ,_, 1,402_CD ,_, or_CC 1,497_CD nt_NNS has_VBZ been_VBN determined_VBN were_VBD included_VBN for_IN comparison_NN ._SENT They_PP are_VBP deposited_VBN under_IN accession_NN nos._NNS ,_, ,_, ,_, to_TO ,_, ,_, ,_, ,_, ,_, ,_, to_TO ,_, to_TO ,_, ,_, ,_, ,_, ,_, to_TO ,_, to_TO ,_, ,_, and_CC to_TO ._SENT All_DT except_IN one_CD of_IN the_DT human_JJ and_CC swine_NN HEV_NP strains_NNS isolated_VBN in_IN Japan_NP are_VBP segregated_VBN into_IN one_CD of_IN three_CD groups_NNS (_( groups_NNS A_DT to_TO C_NP )_) ,_, as_RB indicated_VBN by_IN the_DT shaded_JJ circles_NNS ;_: the_DT one_CD exception_NN is_VBZ swine_NN isolate_NN swJ791_NN ,_, which_WDT is_VBZ close_JJ to_TO the_DT Spanish_JJ strains_NNS (_( Sp1_NP ,_, Sp2_NP ,_, and_CC Sp3_NP )_) ._SENT Bootstrap_NN values_NNS of_IN >70_JJ %_NN are_VBP indicated_VBN for_IN the_DT major_JJ nodes_NNS as_IN a_DT percentage_NN of_IN the_DT data_NNS obtained_VBN from_IN 1,000_CD resamplings_NNS ._SENT TABLE_NN 2_CD |_SYM Profiles_NP of_IN the_DT 11_CD patients_NNS with_IN HEV_NP viremia_NN TABLE_NP 3_CD |_SYM Comparison_NN of_IN various_JJ features_NNS between_IN the_DT HEV_NP RNA-positive_NP and_CC -negative_JJ groups_NNS among_IN the_DT 87_CD patients_NNS with_IN sporadic_JJ ,_, acute_JJ hepatitis_NN of_IN unknown_JJ etiology_NN Infection_NN with_IN HEV_NP is_VBZ widespread_JJ ,_, and_CC hepatitis_NP E_NP is_VBZ endemic_JJ and_CC occasionally_RB epidemic_JJ in_IN many_JJ developing_VBG countries_NNS in_IN Asia_NP ,_, Africa_NP ,_, and_CC Latin_NP America_NP ._SENT In_IN industrialized_JJ countries_NNS ,_, although_IN anti-HEV_NP has_VBZ been_VBN detected_VBN in_IN 4_CD to_TO 36_CD %_NN of_IN healthy_JJ individuals_NNS ,_, sporadic_JJ cases_NNS of_IN hepatitis_NN E_NN not_RB associated_VBN with_IN traveling_VBG to_TO regions_NNS of_IN endemicity_NN have_VBP only_RB rarely_RB been_VBN reported_VBN ._SENT In_IN the_DT present_JJ study_NN conducted_VBN in_IN Japan_NP ,_, where_WRB HEV_NP infection_NN is_VBZ not_RB considered_VBN endemic_JJ ,_, 11_CD (_( 12.6_CD %_NN )_) of_IN 87_CD patients_NNS who_WP had_VBD previously_RB been_VBN diagnosed_VBN with_IN sporadic_JJ acute_JJ hepatitis_NN of_IN non-ABC_NN etiology_NN were_VBD found_VBN to_TO be_VB infected_VBN with_IN HEV_NP ._SENT The_DT prevalence_NN of_IN HEV_NP RNA_NP differed_VBD by_IN age_NN ,_, sex_NN ,_, and_CC geographic_JJ region_NN ,_, being_VBG consistent_JJ with_IN the_DT reported_VBN age-_NN ,_, sex-_NN ,_, and_CC region-dependent_JJ prevalence_NN of_IN anti-HEV_NP IgG_NP in_IN healthy_JJ individuals_NNS in_IN Japan_NP ._SENT Interestingly_RB ,_, in_IN our_PP$ present_JJ study_NN ,_, the_DT prevalence_NN of_IN HEV-associated_JJ hepatitis_NN among_IN sporadic_JJ acute_JJ hepatitis_NN cases_NNS of_IN non-ABC_NN etiology_NN was_VBD significantly_RB associated_VBN with_IN male_JJ sex_NN ,_, older_JJR age_NN (_( >=40_JJ years_NNS )_) ,_, and_CC living_VBG in_IN the_DT northern_JJ part_NN of_IN Japan_NP (_( Hokkaido_NP and_CC Iwate_NP )_) (_( P_NN <_SYM 0.01_CD ,_, P_NN <_SYM 0.005_CD ,_, and_CC P_NN <_0.05, =40_NN years_NNS ,_, and_CC patients_NNS living_VBG in_IN Hokkaido_NP and_CC Iwate_NP ,_, the_DT prevalence_NN of_IN hepatitis_NN E_NN among_IN sporadic_JJ acute_JJ hepatitis_NN cases_NNS of_IN non-ABC_NN etiology_NN is_VBZ estimated_VBN to_TO be_VB 9_CD of_IN 38_CD patients_NNS (_( 24_CD %_NN )_) ,_, 11_CD of_IN 48_CD patients_NNS (_( 23_CD %_NN )_) ,_, and_CC 8_CD of_IN 38_CD patients_NNS (_( 21_CD %_NN )_) ,_, respectively_RB ._SENT Furthermore_RB ,_, the_DT 11_CD patients_NNS with_IN hepatitis_NP E_NP had_VBD markedly_RB elevated_VBN serum_NN transaminase_NN levels_NNS (_( ALT_JJ levels_NNS ,_, 914_CD to_TO 4,850_CD IU/liter_NN ;_: AST_NP levels_NNS ,_, 539_CD to_TO 5,931_CD IU/liter_NN )_) ._SENT When_WRB the_DT evaluation_NN was_VBD restricted_VBN to_TO patients_NNS having_VBG abnormal_JJ ALT_NP and/or_CC AST_NP levels_NNS of_IN >1,000_JJ IU/liter_NN at_IN disease_NN onset_NN ,_, the_DT prevalence_NN was_VBD estimated_VBN to_TO be_VB 11_CD of_IN 49_CD patients_NNS (_( 22_CD %_NN )_) ._SENT Therefore_RB ,_, in_IN Japan_NP ,_, the_DT possibility_NN of_IN the_DT presence_NN of_IN clinical_JJ HEV_NP infection_NN should_MD be_VB taken_VBN into_IN consideration_NN when_WRB clinicians_NNS are_VBP confronted_VBN with_IN patients_NNS with_IN sporadic_JJ acute_JJ hepatitis_NN of_IN non-ABC_NN etiology_NN ,_, paying_VBG special_JJ attention_NN to_TO age_NN ,_, sex_NN ,_, location_NN of_IN residence_NN ,_, and_CC the_DT results_NNS of_IN liver_JJR function_NN tests_NNS ._SENT The_DT limited_JJ numbers_NNS of_IN samples_NNS evaluated_VBN in_IN this_DT study_NN suggest_VBP that_IN a_DT much_RB larger_JJR study_NN with_IN more_JJR patients_NNS is_VBZ needed_VBN to_TO draw_VB a_DT definitive_JJ conclusion_NN ._SENT The_DT source_NN of_IN the_DT HEV_NP variants_NNS in_IN the_DT 11_CD Japanese_JJ patients_NNS studied_VBN is_VBZ unclear_JJ ,_, and_CC it_PP is_VBZ not_RB easy_JJ to_TO trace_VB the_DT origins_NNS of_IN these_DT isolates_NNS ._SENT Patients_NNS 1_CD to_TO 4_CD ,_, living_VBG in_IN Hokkaido_NP ,_, did_VBD not_RB report_VB contact_NN with_IN pigs_NNS or_CC rats_NNS ._SENT However_RB ,_, patients_NNS 5_CD and_CC 6_CD ,_, living_VBG in_IN Iwate_NP ,_, were_VBD a_DT retail_JJ meat_NN dealer_NN and_CC a_DT meat-processing_NN trader_NN ,_, respectively_RB ,_, who_WP were_VBD engaged_VBN in_IN processing_VBG raw_JJ meat_NN such_JJ as_IN beef_NN ,_, pork_NN ,_, and_CC chicken_NN ,_, suggesting_VBG that_IN they_PP were_VBD at_IN increased_VBN risk_NN for_IN zoonotic_JJ HEV_NP infection_NN ._SENT Of_IN note_NN ,_, the_DT HE-JA5_NP isolate_NN from_IN patient_JJ 5_CD and_CC the_DT HE-JA6_NP isolate_NN from_IN patient_JJ 6_CD were_VBD both_DT closely_RB related_VBN to_TO swine_NN HEV_NP isolates_VBZ thus_RB far_RB identified_VBN in_IN Japan_NP (_( isolates_VBZ swJ570_JJ and_CC swJ681_JJ )_) ._SENT HE-JA8_NP was_VBD isolated_VBN in_IN 2001_CD from_IN patient_JJ 8_CD ,_, who_WP was_VBD a_DT farmer_NN working_VBG with_IN pigs_NNS in_IN his_PP$ herd_NN in_IN Iwate_NP ._SENT Considering_VBG the_DT accumulating_VBG lines_NNS of_IN evidence_NN for_IN zoonotic_JJ HEV_NP infection_NN (_( ,_, -_: )_) ,_, it_PP is_VBZ very_RB likely_JJ that_IN he_PP was_VBD infected_VBN with_IN swine_NN HEV_NP from_IN his_PP$ herd_NN ._SENT However_RB ,_, the_DT HE-JA8_NP isolate_NN was_VBD nearer_JJR U.S._NP human_NN and_CC swine_NN strains_NNS (_( US1_NP ,_, US2_NP ,_, and_CC swUS1_JJ )_) ,_, with_IN the_DT highest_JJS nucleotide_NN identity_NN being_VBG 94.4_CD %_NN ,_, than_IN to_TO a_DT human_JJ isolate_NN (_( JRA1_NP )_) or_CC a_DT swine_NN isolate_NN (_( swJ570_NN )_) that_WDT are_VBP believed_VBN to_TO be_VB indigenous_JJ to_TO Japan_NP ._SENT This_DT result_NN indicates_VBZ that_IN HE-JA8_NP may_MD be_VB a_DT U.S._NP strain_NN ._SENT However_RB ,_, the_DT sequence_NN of_IN HE-JA8_NP shared_VBD 98.5_CD %_NN nucleotide_NN identity_NN with_IN that_DT of_IN HE-JA10_NP ,_, which_WDT was_VBD recovered_VBN in_IN 1993_CD from_IN patient_JJ 10_CD ,_, who_WP lived_VBD in_IN Tokyo_NP ._SENT In_IN addition_NN ,_, HE-JA8_NP as_RB well_RB as_IN HE-JA4_NP ,_, HE-JA7_JJ ,_, and_CC HE-JA10_NP shared_VBD 90.5_CD to_TO 99.7_CD %_NN nucleotide_NN sequence_NN identities_NNS with_IN three_CD recently_RB reported_VBD Japanese_NP HEV_NP isolates_VBZ of_IN genotype_NN III_NP (_( JHA-Sap_NP ,_, JKN-Sap_NP ,_, and_CC JMY-Haw_NP )_) which_WDT are_VBP also_RB classifiable_JJ into_IN group_NN B_NN ,_, suggesting_VBG that_IN it_PP is_VBZ more_RBR likely_JJ that_IN these_DT seven_CD HEV_NP isolates_NNS of_IN group_NN B_NN in_IN genotype_NN III_NP are_VBP domestic_JJ and_CC widespread_JJ in_IN Japan_NP ._SENT In_IN this_DT context_NN ,_, comparison_NN of_IN the_DT sequence_NN of_IN isolate_NN HE-JA8_NP from_IN patient_JJ 8_CD and_CC those_DT of_IN HEV_NP strains_NNS from_IN pigs_NNS in_IN his_PP$ herd_NN would_MD be_VB informative_JJ ._SENT HE-JA11_NP was_VBD from_IN patient_JJ 11_CD ,_, who_WP had_VBD been_VBN to_TO Southeast_JJ Asian_JJ countries_NNS including_VBG Malaysia_NP and_CC Indonesia_NP 3_CD and_CC 12_CD months_NNS before_IN the_DT onset_NN of_IN acute_JJ hepatitis_NN ,_, to_TO visit_VB branch_NN offices_NNS outside_IN Japan_NP as_IN an_DT employee_NN of_IN an_DT electrical_JJ equipment_NN manufacturer_NN for_IN periods_NNS of_IN about_RB 1_CD week_NN ._SENT The_DT possibility_NN that_IN this_DT patient_NN was_VBD infected_VBN with_IN HEV_NP in_IN any_DT of_IN these_DT countries_NNS that_IN he_PP had_VBD recently_RB visited_VBN ,_, where_WRB hepatitis_NP E_NP is_VBZ endemic_JJ ,_, cannot_MD be_VB ruled_VBN out_RP ._SENT However_RB ,_, HE-JA11_NP was_VBD closely_RB related_VBN to_TO reported_VBN human_NN and_CC swine_NN HEV_NP isolates_VBZ (_( JRA1_JJ and_CC swJ570_JJ )_) from_IN Japan_NP ,_, as_RB well_RB as_IN to_TO three_CD HEV_NP isolates_NNS (_( HE-JA5_NP ,_, HE-JA6_NP ,_, and_CC HE-JA9_NP )_) recovered_VBD in_IN the_DT present_JJ study_NN from_IN patients_NNS living_VBG in_IN Iwate_NP and_CC Fukushima_NP who_WP had_VBD never_RB been_VBN abr_NN 